| 货号 | MAB2009-SP |
| 别名 | CD55 antigen; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CD55; CR; CRdecay accelerating factor for complement (CD55, Cromer blood group system); CROMDAFcomplement decay-accelerating factor; DAF; decay accelerating factor for complement; TC |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) |
| 目标/特异性 | Detects human CD55/DAF in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross‑reactivity with recombinant human CD97 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize CD55-mediated adhesion of human red blood cells. Hamann, J. et al. (1996) J. Exp. Med. 184:1185. The Neutralization Dose (ND50) is typically 0.5-2 µg/mL in the presence of 5 µg/mL Recombinant Human CD97. |
| 来源 | Monoclonal Mouse IgG2B Clone # 278803 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 1604 (Human); 13136 (Mouse) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | NS0-derived recombinant human CD55/DAF Asp35-Ser353 Accession # P08174.4 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | CD55, also known as DAF or decay-accelerating factor, is a 70‑75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C’ activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1‑4). A hallmark of RCA proteins is the presence of 4 to 30 SCRs (short consensus repeats; also called CCPs for C’ control protein modules) in their plasma-exposed regions. SCRs are a 60‑65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a beta -barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature human CD55 shares 53% and 84% aa identity with mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells (1, 2). Finally, viruses and bacteria are also known to use multiple SCR sites for infection (4). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Adhesion Mediated by CD55 and Neutralization by Human CD55/DAF Antibody. Recombinant Human CD97 (Catalog # 2529-CD), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human CD97 (5 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD55/DAF Monoclonal Antibody (Catalog # MAB2009). The ND50 is typically 0.5-2 µg/mL. |
